Page URL: https://www.bionews.org.uk/page_93478

Stem cell treatment counters kidney rejection in early trial

12 March 2012
Appeared in BioNews 648

Stem cell therapy may remove the need for organ transplant recipients to have lifelong drug treatment to combat the risk of rejection, which would dramatically improve patients' quality of life.

A new therapy technique has been trialled in eight US kidney transplant patients and early results have been published in the journal Science Translational Medicine. One year after the transplant five of the patients managed to avoid taking the usual immunosuppressive medication and two patients were taking lower doses of these drugs than would normally be required. One patient developed viral sepsis – an occasional complication of organ transplantation – and had to have their new kidney removed again.

Dr Suzanne Ildstad, of the University of Louisville, who led the study, said: 'Immunosuppressive medications come with serious side effects with prolonged use including high blood pressure, diabetes, infection, heart disease and cancer, as well as direct damaging effects to the organ transplant. This new approach would potentially offer a better quality of life and fewer health risks for transplant recipients.'

The stem cell therapy effectively alters patients' immune systems, so that they do not recognise the transplanted kidneys as 'foreign' and reject them.

In the technique, the kidney donor is given medication to boost the number of bone marrow stem cells in their blood a month prior to the operation, and a blood donation is collected. The blood is processed to increase both the numbers of stem cells and another cell type the researchers called transplant 'facilitating cells', and frozen until needed.

The kidney recipient then undergoes radiation and chemotherapy to disable their own immune systems in a manner similar to treatment given to leukaemia patients prior to bone marrow transplants. The kidney is then transplanted and one day later the recipient receives a transplant of the stem cells and facilitating cells collected from the donor.

The transplant patient is then prescribed a usual regime of immunosuppressive drugs, but after six months is gradually weaned off them if the stem cell transplant has been successful.

Dr Tatsuo Kawai, a transplant surgeon at Harvard Medical School, who was not involved in the study, wrote a commentary on the new approach in the same journal. He lauded the results, but also said that it was hard to tell from the study how important the facilitating cells were, as there had been no control group where patients underwent the procedure without receiving these cells.

He also added that subjecting transplant patients to a treatment as harsh as radio- and chemotherapy should be carefully considered, especially as the current techniques for kidney transplantation are relatively safe and well understood.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE
28 January 2013 - by Michelle Downes 
In what is thought to be a first, stem cells have been used to generate human kidney tissue...
30 July 2012 - by Dr Greg Ball 
Adult stem cells extracted from liposuctioned fat have been used to grow new blood vessels, according to scientists presenting their work at a conference. The researchers hope that one day their technique could be used in vascular surgery...
16 July 2012 - by Dr Greg Ball 
Two UK newspapers have hailed a potential treatment for osteoarthritis using a patient's own stem cells although results from early studies in animals and patients are yet to be published...
11 June 2012 - by Dr Greg Ball 
Stem cell research isn't a topic you'd expect to see in a comic book, particularly when the aim is to give a realistic insight into the subject, avoiding hype and sensationalism. But that's exactly what 'Hope Beyond Hype', a graphic novel telling the story of stem cell research from discovery to therapy, intends to do...
11 June 2012 - by Dr Maria Teresa Esposito 
Immune rejection, the body's defence mechanism, triggered in response to foreign tissues, is a huge problem for transplant operations. But why does a mother's immune system not reject the developing fetus? The answer may lie in modifications to genes that usually activate part of the immune response, according to scientists...
21 May 2012 - by Victoria Kay 
The world's first stem cell drug has been approved by Canadian authorities. US biotech company, Osiris Therapeutics, has been given the go-ahead to market its drug, Prochymal, for the treatment of graft-versus-host-disease (GvHD) in children who fail to respond to steroids....
10 October 2011 - by George Frodsham 
Scientists have found a new method of suppressing the automatic rejection of donated kidneys in transplant patients, by using the donor's stem cells. In a small trial carried out at Stanford University, California, eight out of 12 patients were able to stop taking anti-rejection drugs, which are usually a lifelong necessity, following this treatment....
18 April 2011 - by Dr Rosie Gilchrist 
Scientists at Edinburgh University have grown kidney structures in the laboratory in a step they hope will lead to organs being grown for transplant patients from their own stem cells...
22 March 2010 - by Dr Vivienne Raper 
A UK child has become the world's first to receive a full windpipe transplant using an organ built from his own stem cells...
7 June 2009 - by Heidi Colleran 
A Chinese research team has brought the quest for a genetically modified pig, capable of providing viable organs for transplant patients, a step closer. Scientists at the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) have succeeded in creating the first pig stem cells in the laboratory, the Journal of Molecular and Cell Biology reports. These cells could be used to create 'transgenic' pigs, which have been genetically altered so that their organs would not be rejected by the hum...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.